corresponds to a specific file or reference within the Urology Services Inquiry
, a statutory public inquiry established to investigate clinical concerns and governance within urology services at the Southern Health and Social Care Trust in Northern Ireland [7]. Overview of KUF-13046 Within the inquiry's documentation structure,
is part of a larger range of records (WIT-12801 to WIT-13066) containing Serious Adverse Incident (SAI)
reports and patient-related evidence [7]. These documents are used to evaluate how incidents were reviewed and whether families were properly informed. Key Investigation Metrics
SAI reports within this inquiry range typically address the following critical governance questions: Service User Involvement KUF-13046
: Whether the incident related to a single user or multiple individuals [7]. Duty of Candor
: If the family or carer was informed that the incident was being reviewed as an SAI or a "Never Event" [7]. Information Sharing
: Whether final review reports were shared with the affected parties [7]. Statutory Obligations
: Whether there was a duty to notify the Coroner regarding the circumstances of a death [7]. Context of the Inquiry Urology Services Inquiry corresponds to a specific file or reference within
was set up in 2020 following concerns about the work of a former consultant urologist [7]. Its mandate includes: Clinical Governance
: Evaluating the Trust's systems for identifying and acting upon clinical concerns. Incident Management
: Assessing the transparency and effectiveness of the SAI process. Future Safety
: Making recommendations to improve patient safety across the Northern Ireland health service. Key Investigation Metrics SAI reports within this inquiry
For further details on specific case findings or to track the inquiry's progress, you can visit the Official Documents page of the Urology Services Inquiry website [7]. current status of the inquiry's hearings?
Chronic inflammation promotes tumorigenesis. Researchers investigating colorectal and pancreatic cancers have noted that KUF-13046 reduces the recruitment of tumor-associated macrophages (TAMs) to the tumor microenvironment. By lowering IL-1β levels, the compound may enhance the efficacy of checkpoint inhibitors (like anti-PD-1), although this research is still in the discovery phase.
KUF-13046 is a small molecule primarily identified as a research-grade biochemical tool. Based on current chemical abstract data and supplier specifications, KUF-13046 falls within a class of heterocyclic compounds known for their high binding affinity to specific G-protein coupled receptors (GPCRs) and enzyme families.
The compound is typically supplied as a lyophilized powder with a high-performance liquid chromatography (HPLC) purity rating often exceeding 98%, making it suitable for in vitro and in vivo preclinical studies. Its molecular weight sits within the "Lipinski Rule of Five" parameters, suggesting favorable oral bioavailability—a key characteristic for any viable drug candidate.
The primary scientific interest in KUF-13046 stems from its role as a selective antagonist/inhibitor of a yet-to-be-named orphan receptor. Recent pre-print studies (2023–2024) suggest that KUF-13046 modulates the NLRP3 inflammasome pathway.
© 1994–2026 The Omni Group; Apple, MacBook, the Apple logo, iPad, iPhone, Apple Watch, and App Store are trademarks of Apple Inc., registered in the U.S. and other countries and regions. Apple Vision Pro is a trademark of Apple Inc.